

Supplementary Table 1. Success rate of second-line *H. pylori* eradication therapy according to first-line *H. pylori* eradication therapy

Variable	14-day rabeprazole-based		14-day tegoprazan-based	
	bismuth-containing therapy (n=57)	<i>p</i> -value	bismuth-containing therapy (n=25)	<i>p</i> -value
First-line <i>H. pylori</i> eradication therapy		0.188		0.837
7-day tegoprazan-based triple, n/N (%)	17/22 (77.3)		5/5 (100.0)	
14-day tegoprazan-based triple, n/N (%)	6/6 (100.0)		7/7 (100.0)	
14-day rabeprazole-based triple, n/N (%)	6/8 (75.0)		0/0 (N/A)	
10-day rabeprazole-based concomitant, n/N (%)	0/0 (N/A)		6/7 (85.7)	
10-day tegoprazan-based concomitant, n/N (%)	20/21 (95.2)		5/6 (83.3)	

n, number of patients with successful *H. pylori* eradication; N, number of patients; N/A, not applicable.